Background aims. Dental pulp stromal cells (DPSC) are considered to be a promising source of stem cells in the fi eld of regenerative therapy. However, the usage of DPSC in transplantation requires large-scale expansion to cater for the need for clinical quantity without compromising current good manufacturing practice (cGMP). Existing protocols for cell culturing make use of fetal bovine serum (FBS) as a nutritional supplement. Unfortunately, FBS is an undesirable additive to cells because it carries the risk of transmitting viral and prion diseases. Therefore, the present study was undertaken to examine the effi cacy of human platelet lysate (HPL) as a substitute for FBS in a large-scale set-up. Methods . We expanded the DPSC in Dulbecco ' s modifi ed Eagle ' s medium -knock-out (DMEM-KO) with either 10% FBS or 10% HPL, and studied the characteristics of DPSC at pre-(T25 culture fl ask) and post-(5-STACK chamber) large-scale expansion in terms of their identity, quality, functionality, molecular signatures and cytogenetic stability. Results . In both pre-and postlarge-scale expansion, DPSC expanded in HPL showed extensive proliferation of cells ( c. 2-fold) compared with FBS; the purity, immune phenotype, colony-forming unit potential and differentiation were comparable. Furthermore, to understand the gene expression profi ling, the transcriptomes and cytogenetics of DPSC expanded under HPL and FBS were compared, revealing similar expression profi les. Conclusions . We present a highly economized expansion of DPSC in HPL, yielding double the amount of cells while retaining their basic characteristics during a shorter time period under cGMP conditions, making it suitable for therapeutic applications.
Introduction
The transplantation of human dental pulp stem/ stromal cells (DPSC) in human mandible bone (1) has created a signifi cant impact in the fi eld of regenerative medicine. For the fi rst time, this has moved dental stem cell research from the bench to the bedside. Human DPSC originate from a neuralcrest lineage and can be obtained non-invasively from teeth that are extracted for clinical reasons and usually discarded as biologic waste (2,3). Studies have shown that DPSC are capable of differentiating into fully functional neuronal cells (4), odontoblasts (5) , endothelium (5) , hepatocytes (6) and pancreatic cells (7), and have shown some remarkable outcomes in pre-clinical studies (8,9). Thus, it will not be surprising if DPSC emerge as a potent surrogate for traditionally used bone marrow (BM) mesenchymal stromal cells (MSC) in human clinical trials. This paradigm shift opens avenues into the treatment of debilitating diseases with a tailormade choice of stem cells in anticipation of achieving maximum effi cacy with regenerative medicine. However, just like any other MSC source, the use of DPSC in transplantation requires large-scale expansion of cells in order to cater for the need for clinical quantity.
In most clinical trials, including the fi rst human DPSC transplantation, fetal bovine serum (FBS) has been used as the main nutritional supplement. However, the use of xenogeneic serum is complicated because of high lot-to-lot variability coupled with the risk of transmitting infectious agents and immunizing effects (10, 11) . Therefore there is always a need to search for alternative sources to replace FBS, but these substitutes must show competitive results. A chemically defi ned xenofree medium would be the preferred solution; however, such a formulation that allows for both isolation and expansion has not been achieved thus far (12). In addition, making a chemically defi ned media as good as FBS would perhaps be more expensive than FBS itself, which ultimately would hamper production at large scales.
Conversely, human blood products, such as autologous and allogeneic human serum, human plasma, cord blood serum and human platelet derivatives, including platelet lysate (PL) and platelet-released factors (13 -16), have been introduced increasingly in stem cell therapy as a compelling substitute for FBS. The buffy coat-derived platelets are of particular interest because they do not compete with erythrocyte and plasma preparations for the limited available blood donations (17). This is because the platelets are separated from the white and red blood cell fractions and can be concentrated to at least 1 ϫ 10 9 platelets/mL by centrifugation. The release of growth factors and mitogens stored in alpha granules of platelets may be induced by platelet activation by thrombin or cell fragmentation during repeated freeze -thaw cycles (18) . Among the persuasive mediators released from platelets are adhesive proteins, coagulation factors, mitogens, protease inhibitors and proteoglycans (19) . Hence, human platelet lysate (HPL) may replace FBS in many cell culture systems that have previously been thought to be solely dependent on the presence of FBS.
Although much of the past literature has focused on BM MSC cultured in HPL, little information is available on the effect of HPL on the proliferation and differentiation capacity of DPSC at a clinical scale of manufacture. We have already described a protocol for optimizing the culture conditions and seeding density of DPSC (20). Here, we expand the protocol for the large-scale production of pooled DPSC by using HPL, which reproducibility resulted in more than 3 ϫ 10 8 cells in passage 2. To exclude the possibility that large-scale expansion can affect immunomodulation, the effect of up-scaled DPSC in HPL on the expression of HLA-DR was accessed. Karyotype analysis was performed to evaluate numerical and structural abnormalities, if any, in the largescale expanded DPSC, and they were assessed for the expression of stem cells, lineage-specifi c oncogenes and tumor-suppressor genes. We present procedures for generating clinical quantities of human DPSC cultured in HPL and FBS with retained differentiation potential, cell-surface antigens and chromosomal stability.
Methods

HPL preparation
PL was prepared from 30 -40 donors who had donated at the University of Malaya Blood Bank (Kuala Lumpur, Malaysia). Briefl y, whole blood (WB) was collected into a quadruple blood-bag system (Baxter Health Care Corporation, Deerfi eld, IL, USA) and centrifuged at 4250 g for 13 min at 22 ° C to separate the plasma and buffy coat. Platelet-rich plasma (PRP) was prepared by mixing 4 units buffy coat (from donor group O) and 1 unit plasma (from donor group AB). Immediately after preparation, the PRP was frozen down to -80 ° C and subsequently thawed at 37 ° C to obtain platelet-released growth factors. Ten to 12 thawed PRP units, now called HPL, were pooled to prepare a standardized pooled HPL (pHPL). The pHPL was centrifuged at 4000 g for 15 min at 4 ° C to remove the platelet fragments. The supernatant plasma was fi ltered further using a 40-m M fi lter (BD Biosciences, Franklin Lakes, NJ, USA) and transferred into 50-mL vials (BD Biosciences). Sterility tests, such as endotoxin and mycoplasma, were conducted, and 2 U/mL heparin (Heparinol; Ain Medicare Sdn Bhd, Kota Bahru, Malaysia) were added into the pooled HPL before releasing it for experimental use. A schematic view of pooled HPL is illustrated in supplementary Figure 1 .
Isolation of dental pulp tissues
Sound, intact, human third molars from adults ( n ϭ 9, 24 -35 years of age) were collected with informed consent from patients undergoing extraction at the Department of Oral and Maxillofacial Surgery, University of Malaya, under approved guidelines set by the Medical Ethics Committee, Faculty of Dentistry, University of Malaya [medical ethics clearance number DF CD0907/0042(L)]. Under sterilized conditions, the root surface of the tooth was cleaned with 100% povidone-iodine (Sigma-Aldrich, St Louis, MO, USA) and the pulp extirpated within 2 h postextraction. Thereafter, the tissue was kept in a 1.5-mL tube containing 1 ϫ Dulbecco ' s modifi ed Eagle ' s medium -knock-out (DMEM-KO), 10% FBS, 2% Pen-Strep, 5% GlutaMax, 100 m g/mL ascorbic acid and 1 ϫ insulin-transferrin-selenium (ITS). Then it was transported to a nearby current good manufacturing 
Human BM MSC isolation
Human BM samples were taken after written consent using guidelines approved by the Malayan Ministry of Health. BM-derived MSC cultures were established from pooled donors ( n ϭ 3, age range 18 -25 years) as described previously (21). The BM MSC were cultured under identical culture conditions as those of DPSC.
Colony-forming units
DPSC cultures (HPL and FBS) from the pre-and post-large-scale expansion were harvested and the total cell numbers determined. Next, the number of colony-forming units (CFU) was determined by replating 100 cells in a 35-mm dish followed by 2 weeks of culture with either HPL or FBS. After 14 days in culture, the cells were fi xed in 100% methanol for 20 min followed by 3% crystal violet staining. Colonies larger than 2 m M were counted. The CFU equaled the total number of colonies divided by the initial number of cells multiplied by 100.
Growth kinetics of DPSC
Cells were passaged and counted once they reached a confl uence of 80 -90%. The PD rate was determined by using the formula: X ϭ [log10( n h ) -log10( n 1 )]/ log10, where n h ϭ harvested cell number and n 1 ϭ plated cell number. In addition, the generation time or population doubling time (PDT) was calculated by using the formula: X ϭ log2 ϫ Δ t /log( n h ) -log( n 1 ).
Immunophenotyping
DPSC cultured in HPL and FBS at pre-and postlarge-scale expansion were taken for fl ow cytometric analysis at passage 2. The following antibodies were used to mark the cell-surface epitopes: CD90 -phycoerythrin (PE), CD44 -PE, CD73 -PE, CD166 -PE, CD34 -PE, CD45 -fl uoro-isothyocyanate (FITC) and HLA-DR -FITC (all from BD Pharmingen, Franklin Lakes, NJ, USA) All analyzes were standardized against negative control cells incubated with isotype-specifi c IgG1 -PE and IgG1 -FITC (BD Pharmingen, Franklin Lakes, NJ, USA). At least 10 000 events were acquired on a Guava Technologies fl ow cytometer and the results were analyzed using Cytosoft (version 5.2; Guava Technologies, Franklin Lakes, NJ, USA).
Differentiation of DPSC
DPSC cultures (HPL and FBS) were trypsinized with 0.05% trypsin (Invitrogen) and plated at a density of 1000 cells/cm 2 in 6-well plates and grown to confl uence in culture medium supplemented with practice (cGMP) certifi cated laboratory for isolation of the cells.
Isolation of primary cells
DPSC primary cultures were established as described previously (20) . In brief, the pulp tissue was minced into small fragments prior to digestion in a solution of 3 mg/mL collagenase type I (Gibco, Grand Island, NY, USA; http://www.invitrogen.com) for 40 min at 37 ° C. After neutralization with 10% FBS (lot number ATJ33090; Hyclone, South Logan, UT, USA; www.thermo.com/hyclone), the cells were centrifuged and seeded in a T75 culture fl ask (BD Biosciences) with culture medium containing DMEM-KO (Invitrogen, Carlsbad, CA, USA; www. invitrogen.com), 0.5% and 10000 m g/mL penicillin/ streptomycin (Invitrogen), 1% 1 ϫ Glutamax (Invitrogen) and 10% FBS, in a humidifi ed atmosphere of 95% air and 5% CO 2 at 37 ° C. Non-adherent cells were removed 48 h after initial plating. The medium was replaced every 3 days until the cells reached 80 -90% confl uency.
In vitro expansion of human dental stem cells from single and pooled donors
Experiments were carried out in two sets. In the fi rst set, primary DPSC from nine donors were cultured separately in HPL and FBS by using T25 fl asks (BD Biosciences) up to passage 5. In the second set, three lots of pooled DPSC were created randomly for HPL and FBS, whereby each lot comprised equal numbers of primary DPSC from three donors. The cells were cultured in T25 fl asks up to passage 5. In all experiments, the seeding density of DPSC was kept at 1000 cell/cm 2 , as described previously (20). The proliferation and population doubling (PD) time of single and pooled DPSC were assessed.
Clinical-scale expansion procedure
The pooled DPSC were used for the large-scale expansion experiment. These cells were cultured at 1000 cells/cm 2 in either 10% HPL or 10% FBS supplemented with DMEM-KO (Invitrogen), 0.5% and 10000 m g/mL penicillin/streptomycin (Invitrogen) and 1% 1 ϫ Glutamax (Invitrogen) using a T25 fl ask (designated as pre-large-scale expansion; total surface area 25 cm 2 ; BD Biosciences) and BM MSC (control) and DPSC cultured in either HPL or FBS at pre-and post-large-scale expansion. For data analysis, the ABI PRISM 7900HT sequence detection system software (SDS) calculated the levels of target (DPSC expanded under HPL and FBS at pre-and post-large-scale expansion) gene expression in samples relative to the level of expression in the calibrator (BM MSC) by using the comparative CT method ( Δ Δ CT ). For estimation of the fold change by TLDA when the initial transcript levels were undetectable, the initial cycle threshold (CT) value was assigned 39, which could lead to a possible underestimation of the actual fold change.
Reverse transcription -polymerase chain reaction
Total RNA was extracted using TRIZOL (Invitrogen) according to the manufacturer ' s instructions. The RNA was reverse-transcribed (RT) into cDNA using Superscript II reverse transcriptase (Invitrogen) according to the manufacturer ' s instructions. cDNA amplifi cation was performed in a thermocycler using Taq polymerase supplied with KCl buffer and 1.5 m M MgCl 2 (Invitrogen) at 94 ° C/1 min, 58 ° C/30 s, 72 ° C/1 min. Polymerase chain reaction (PCR) products were resolved on 1.5% agarose (Invitrogen) gel and run in 1 ϫ Tris borate -ethylene diamine tetra acetic acid (EDTA) buffer. The primer sequences are tabulated in Table I . The expression of some of the primers in the semi-quantitative RT-PCR analysis was quantifi ed using SYBR green master mix (Applied Biosystems). PCR reactions were run on an ABI 7900HT RT-PCR system (Applied Biosystems) and SDS v2.1 software was used to analyze the results. All measurements were normalized with 18S rRNA.
Karyotyping
The cytogenetic stability of DPSC was evaluated using conventional karyotyping. After pre-and postlarge-scale expansion, cells were incubated with 0.1 m g/mL colcemid (Gibco) for 2 h in 5% CO 2 at 37 ° C. The chromosome profi le was assessed by trypsin/ Giemsa staining. A minimum of 25 metaphases from each sample was counted.
Product quality control test
The fi nal cell products underwent all the recognized quality control tests to adhere to specifi c criteria, including the following. (i) The sterility of the fi nal product (at both pre-and post-large-scale expansion) supernatant was performed by direct inoculation of at least 1% nonvented aerobic FA medium and Bact/ALERT FN anaerobic medium and measured. Adequacy was reached when all cultures scored either FBS or HPL. Then the cells derived from HPL and FBS cultures were washed with Dulbecco ' s phosphate-buffered saline (DPBS; Invitrogen) and the different induction media added. Adipogenic differentiation was initiated by inducing the cells with 200 m M indomethacin, 0.5 m M 3-isobutyl-1-methyxanthine (IMBX), 10 m g/mL insulin and 1 m M dexamethasone (all reagents from Sigma-Aldrich). Lipid droplets in the adipocytes generated were visualized by staining with Red Oil staining (SigmaAldrich). The percentage of adipocytes was counted as described previously (22). Briefl y, the nuclei of the cells were counterstained with hematoxylin and the number of oil droplets attached to the cells counted. The percentage of adipocytes was estimated by counting 500 total cells in multiple fi elds.
For chondrogenic differentiation, the cells were supplemented with ITS ϩ 1 (Sigma-Aldrich), 50 m M L -ascorbic acid-2 phosphate, 55 m M sodium pyruvate (Invitrogen), 25 m M L -proline (Sigma-Aldrich) and 10 ng/mL transforming growth factor-beta (TGF-β ; Sigma-Aldrich). Assessment of proteoglycan accumulation was visualized by Alzarin Blue staining (Sigma-Aldrich). The osteogenic differentiation was stimulated in a 3-week culture with 10 -7 M dexamethasone, 10 m M β -glycerol phosphate (Fluka, Buchs, Switzerland) and 100 m M L -ascorbic acid-2 phosphate. Assessment of calcium accumulation was visualized by Von Kossa staining (Sigma-Aldrich). The percentage of calcium deposition was counted as described previously (23). Briefl y, the entire 35-mm dishes were scanned in color using a fl atbed scanner (Canon) at a resolution of 800 -1200 p.p.i. The images were then uploaded into an image database that was complied with Image-Pro Plus software (Media Cybernetic LP, Silver Spring, MD, USA; http://www.mediacy.com). The lower detection limit for the calcium matrix was 0.025 mm 2 . Osteogenic differentiation was presented as the mineralized area in the total culture area.
Human TaqMan low-density array
A human TaqMan low-density array (TLDA; Applied Biosystems, Carlsbad, CA USA; www. appliedbiosystems.com) containing a well-defi ned set of validated gene expression markers to characterize embryonic stem (ES) cells was used for analyzing the expression of a focused panel of pluripotent and stem cell markers. The 384 wells of each TLDA card were pre-loaded with fl uorogenic probes and primers (Applied Bioystems). The cDNA was loaded on the microfl uidic cards for thermal cycling on an ABI PRISM 7900HT sequence detection system (Applied Biosystems). Expression values for target genes were normalized to the expression of 18S rRNA. Transcriptional analysis was performed for We found that single donor-derived DPSC cultured in HPL grew at faster rates and yielded higher cell numbers compared with single donor-derived DPSC cultured in FBS. DPSC cultured in HPL resulted in an average maximal cell number of 18.91 Ϯ 0.94 ϫ 10 6 cells, while FBS cultures resulted in an average of 10.46 Ϯ 1.9 ϫ 10 6 cells ( P Ͻ 0.05) at the end of fi ve passages ( Figure 1E ). Again, under HPL culture conditions, DPSC displayed lower PDT compared with those cultured under FBS, with a peak at 38.57 Ϯ 2.82 h and 51.86 Ϯ 5.23 h, respectively ( P Ͻ 0.05), as shown in Table II . To assess the effect of HPL on the pooled DPSC, cell number as well as PDT was assessed at the end of the passage 5 with identical culture conditions, seeding density and tissue fl ask. Astoundingly, after fi ve passages, we obtained 25.29 Ϯ 1.85 ϫ 10 6 and 14.64 Ϯ 2.1 ϫ 10 6 ( P Ͻ 0.05; Figure 1F ) expanded DPSC derived from pooled donors corresponding to an average PDT of 22.22 Ϯ 2.49 h and 31.6 Ϯ 0.86 h for HPL and FBS cultures, respectively ( P Ͻ 0.05; Table III), which were higher compared with single donor-derived DPSC. As we needed large amounts of cells (approximately 3.5 million cells for every 5-cell stack), we used the DPSC derived from pooled donors to initiate the large-scale experiment.
Clinical-scale expansion of DPSC
Three sets of primary cells were used in this study, each set comprising a pooled sample from three donors. At passage 1, the cells were cultured in either HPL or FBS at a density of 1000 cells/cm 2 . After the cells reached confl uency, they were trypsinized and subsequently cultured. In order to maintain uniformity in the results obtained, we compared pre-(cells cultured in T25 culnegative after a 14-day culture. (ii) The endotoxin content was analyzed using a Limulus amebocyte lysate (LAL) test according to European Pharmacopeia (PBI S.p.A, Milano, Italy). Adequacy was Ͻ 2.5 EU/mL). (iii) Mycoplasma contamination was detected with a mycoplasma enzyme-linked immunosorbent assay (ELISA)-PCR kit (Roche, Mannheim, Germany; www.roche-applied-science.com). Adequacy was when no contamination was detected.
Statistical analysis
The descriptive statistical analyzes were performed using the software SPSS for Windows (version 11.0; SPSS Predictive Analytics, Chicago, IL, USA; http:// www.spss.com). The data were analyzed using oneway analysis of variance ( ANOVA ). The signifi cance level was set at P ϭ 0.05. Tukey post-hoc multiple comparison tests were carried out to determine the differences between groups.
Results
Proliferative response of single and pooled DPSC in HPL and FBS
Individual digestion of pulp tissues from donors ( n ϭ 9; male) yielded approximately 0.8 Ϯ 0.2 ϫ 10 6 cells/donor dental tissue. Morphologically, DPSC expanded in the presence of HPL were smaller, spindle-shaped cells and highly dense overlapping cells compared with only loosely connected cells in FBS ( Figure 1A,B) . The colony-forming properties of DPSC expanded in HPL and FBS were assessed. The CFU were highly packed in cells expanded in HPL compared with cells expanded in FBS (Figure 1C,D) . expansion were checked with 7-amino-actinomycin D (7-AAD) and found to be more than 80%.
In vitro differentiation potential of DPSC after clinical-scale expansion
Osteogenic differentiation was confi rmed in DPSC cultured in HPL and FBS at pre-and post-large-scale expansion by the deposition of a silver-stained mineralized matrix (supplementary Figure 4) . At pre-largescale expansion, the percentage mineralization was 65 Ϯ 2 for cells cultured in HPL and 69 Ϯ 5 for FBS, respectively (Table II) (Table  IV) and the percentage was almost retained at the post-large-scale expansion. Chondrogenic differentiation was confi rmed by the formation of spheres in the micro-mass culture and the secretion of stainable cartilage-specifi c proteoglycans. Both cells cultured under HPL and FBS demonstrated a cartilage-like phenotype with chondrocyte-like lacunae at postlarge-scale expansion (supplementary Figure 4) .
DPSC cultured in HPL express a similar functional classifi cation of stem cells and early lineage genes as that of FBS after clinical-scale expansion
To assess whether the DPSC cultured under HPL were different from FBS, we performed a series of pluripotent gene analyses on cells at pre-and postlarge-scale expansion by using BM MSC as a calibrator (control). In order to evaluate the transcriptional changes between the different cultured cells, we focused on genes that had a Ͼ 1.5-fold change, as shown in Figure 2A . Interestingly, the expression of stem cell markers such as OCT4, SOX2 and ture fl asks) and post-(5-STACK chambers) expansion cultured in either HPL or FBS by confi ning our data to passage 2. In the large-scale expansion experiment, DPSC expanded in HPL produced a higher yield (Table IV) .
Immunophenotype analysis of up-scaled DPSC
We compared the immunophenotype of the fi nal population obtained from passage 2 and it was found that cells expanded in HPL or FBS did not diverge from each other at either the pre-or post-largescale expansion of DPSC (Table IV; supplementary Figure 3 ; P Ͼ 0.05). The cells consistently shared the same ' mesenchymal stromal cell phenotype ' as recommended by the International Society for Cellular Therapy (ISCT) (24), which is more than 80% positivity for CD44, CD73 and CD90 and negativity for CD45 and CD34. We also compared the HLA-DR expression at pre-and post-large-scale expansion obtained from DPSC expanded under HPL and FBS, which expressed less than 2% ( P Ͼ 0.05); hence it could be concluded that DPSC were poorly immunogenic in vitro . The viability of the harvested DPSC at pre-and post-large-scale between the groups, whereas the p16 gene was not expressed in any culture conditions. However, the difference was not statistically signifi cant. Notably, the mRNA expression of other groups, DNA repair enzymes such as RAD51, ERCC3 and XRCC4, were also not statistically signifi cantly changed ( P Ͼ 0.05) between pre-and post-large-scale expansion cultures, although some variations were noted, especially for the XRCC4 gene ( Figure 3E,F) .
Quality control of up-scaled DPSC
All DPSC products obtained at pre-and post-largescale expansion were tested for all standard quality controls required for cell therapy products produced in cGMP conditions, including sterility, endotoxin and mycoplasma testing. The cell products were found to fall within the acceptable ranges in all cases and, as such, were notionally releasable for clinical use (Table IV) .
Discussion
We have demonstrated that the effi cacy of DPSC cultured using HPL is highly enhanced in a large-scale NANOG, as well as neuro-ectoderm markers (25) such as NES, GBX2, PAX6 and TH, was retained after post-large-scale expansion for cells cultured in HPL and FBS. Quantitative RT-PCR and realtime PCR confi rmed the fi delity of the array data, where selected genes were expressed in accordance with their differential expression pattern in the array ( Figure 2B,C) .
Cytogenetic stability of the up-scaled DPSC
To evaluate numerical and structural chromosomal abnormalities in DPSC after large-scale expansion under different media compositions (HPL and FBS), samples were guanine-thymine-guanine (GTG)-banded. None of the samples was found to be abnormal, indicating stable karyotypes ( Figure 3A -D) . There are reports that suggest that MSC, when cultured in vitro for long periods, can undergo spontaneous transformation and immortalize at a high frequency (26). We looked for signs of transformation in our cells cultured in HPL and FBS in a large-scale set-up, compared with pre-large-scale expansion. An increase in the expression level was observed for some of the tumor suppressor genes, such as p21 and p53, 2 ϫ 10 6 MSC/kg body weight for transplantation (27), although an optimal MSC dose needs to assessed for different indications. This could certainly reduce the cost of large-scale production by 50%. Not only the set-up. The large-scale expansion of DPSC using HPL was suffi cient to treat four patients, compared with FBS which accommodated up to two patients, considering a 70-kg patient needs approximately us to generate suffi cient quantities of clinical-grade DPSC in vitro within a reasonable time frame. It is a well-established fact that dental stem cells depend heavily on donor-to-donor variability and age (35). Hence, it is almost not possible for all donors to attain the same level in a large-scale set-up. By pooling different donors from different age groups, we believe there is a possibility that cells from a single donor (or donors) with faster growth rates, may provide a more optimal culture result.
In addition, MSC enter senescence almost undetectably from the moment of in vitro culturing (36), therefore it is much better to consider them for cell and gene therapy at early passages. Despite the fact that human MSC are not prone to spontaneous transformations, and quite a few reports suggest normal karyotypes and DNA copy numbers in long-term cultures of MSC (37), the emergence of tumorigenic populations within long-term in vitro culture of BM MSC has been described (38). Thus we postulate that large-scale in vitro expansion at later passage may lead to genetic and epigenetic instabilities.
A process amenable for cGMP manufacture does not simply require the development of a large number of cells, but also replicable tests to establish the quality of the end product. Towards this end, we have employed a set of expression analyzes and identifi ed a panel of immunophenotype markers that could be used to assess rapidly the quality of the end product. Phenotypically MSC express a number of markers, unfortunately none of which is specifi c. For all the culture conditions investigated, cells expressed in the immunophenotype are within the list of markers proposed by the ISCT (24). As HLA-DR molecules are substantial regarding T-cell stimulation and immunorecognition (39), we examined the expression level of this marker. The fl ow cytometry analysis demonstrated that the cells obtained from large-scale expansion did not express the HLA-DR signifi cantly, hence clearly demonstrating the capacity of DPSC as immune-privileged cells. This result was in line with previous studies on using HPL (11, 40) . Despite this, our fi ndings of immunogenic studies showing an absence of HLA-DR may not be suffi cient to brand them as non-immunogenic. Further studies focusing on the immunomodulation activities should be executed to understand the allostimulatory role of DPSC on T cells, if any.
We also found that large-scale expansion in HPL did not signifi cantly infl uence the tri-lineage differentiation capacity. Our fi ndings are in agreement with those published previously (30) , that MSC expanded in the presence of PL retains its ability to differentiate into osteogenic, adipogenic and chondrogenic lineages. Our data thus confi rmed yet another functional similarity between various MSC using HPL, despite their cell yield, but also the time to reach a suffi cient number, is important in certain clinical and research settings; unexpectedly, we found that the cells reached 90% confl uency within 10 -14 days of culture in HPL, compared with 18 -21 days in FBS. Our studies are also in line with many published reports on the use of HPL in culture systems, in which culturing of cells under HPL has massively improved the yield of the cells (15,28 -30) . Of note, our large-scale expansion of DPSC has shown for the fi rst time proof of the principle, exhibiting immensely high expansion kinetics of DPSC in HPL compared with FBS.
It is still unclear why HPL has a stronger mitogenic effect than FBS on DPSC. Previous studies have shown platelet granules contain many growth factors, including platelet-derived growth factor (PDGF), fi broblast growth factor (FGF), insulinlike growth factor (IGF), TGF-β and platelet-derived epidermal growth factor (PDEGF) (31), and these growth factors have been shown to enhance MSC expansion in in vitro conditions (32). It should be noted that the level of growth factors varies considerably between species, with the highest levels found in human PL, followed by goat and rat PL (31). Accordingly, we postulate that the complexity and composition of mammalian platelets may depend on their evolutionary hierarchy, the maximum being obtained in primates compared with other classes of mammals, making human platelets the best available source for large-scale serum-free culture of DPSC.
As the starting material (tissue) for the isolation of DPSC was small, it was almost impossible to scale-up the dental pulp stem cells from one donor to cater for the quantity needed for clinical applications at early culture stages. This is because approximately 3.5 million cells are needed to initiate up-scaling of cells in a 3180-cm 2 area culture fl ask (considering 1000 cells/cm 2 ). Based on this formula, the large-scale expansion for an autologous (singledonor) transplantation is only feasible at passages 4 -5 compared with the large-scale expansion for an allogeneic (multiple-donor) transplantation, which can be initiated as early as passage 2.
Pooling of donors may be necessary and specifi c for up-scaling of dental pulp stem cells; largescale production of other types of stem cells, such as Wharton ' s jelly, does not require pooling of donors because it has been reported that a single umbilical cord is able to generate more than 1 ϫ 10 8 cells within 14 days of culture (33). Nonetheless, this method has been used in the culture of BM MSC, such as as reported by Chase et al. (34) . In their study, they used pooled BM MSC to overcome the donor -donor inconsistency and provide a reliable and unfailing population of MSC for experimentation. We agree with these arguments; the pooling of DPSC enabled despite retaining environmentally friendliness without compromising the ethical and quality standards for human stem cell therapy. location in vivo being associated with distinct sites. A previous study has shown that DPSC have a greater propensity towards ectoderm lineage compared with BM MSC (41). Interestingly, the striking feature from the present results is the ability of the cells to retain most of the ectoderm/neuronal gene expression levels at large-scale expansion. Hence we propose that using HPL as a nutrient supplement in DPSC culturing will be more cost-effective, especially for clinical treatment related to neuro-ectoderm diseases. Furthermore, we looked for signs of transformation markers in our experimental procedure. Despite the enormous cell growth observed in cells cultured in HPL, our study showed that there were no signifi cant differences in terms of gene expression in the list of commonly used transformation markers. One of the possible reasons is that the expression of tumor suppressing genes (p53, p21 and p16) and chromosomes-myelocytomatosis (c-Myc) is closely associated with cell aging or senescence (42) and past reports have stated that, in approximately 20 PD in vitro , MSC culture enter a senescence phase (43). However, this did not occur in our study, as the PD that we obtained with the large-scale expansion was less than 10. With these data and the retention of a normal karyotype, as demonstrated in the present study, we could show the genetic stability of cGMPscaled DPSC cultured in HPL. Finally, we mimicked the cGMP process in releasing cells for transplantation by testing our products at the end of a large-scale expansion with the complete series of standardized quality controls in our cGMP facility and found them to be always passable for clinical use, thus confi rming the reproducibility and suitability of the expansion in cGMP conditions. Although human components can be prepared easily according to blood banking standards, there remains the risk of sensitization by blood group substances or by adventitious agents not screened by routine blood donor testing. The implementation of further procedures, such as quarantine storage and pathogen inactivation, for large-scale cGMPcompliant HPL manufacturing may ensure the highest possible quality standards (44). The availability of donors for HPL over a long period is also a subject to be thought of. In summary, although the culture medium described by us is not clear of xenogeneic and serum-free components, we have shown that DPSC cultured in HPL can be scaled-up effi ciently to obtain clinically relevant cells while retaining their basic MSC characteristics. Furthermore, this time-saving methodology of large-scale expansion of DPSC in HPL can be used for autologous as well as allogeneic transplantation, depending upon the urgency and nature of the disease within a limited time period. Nevertheless, it always a matter of choice to make it cost-effective For personal use only.
